Analysts’ Top Healthcare Picks: Zymeworks (ZYME), ThermoGenesis Holdings (THMO)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYMEResearch Report), ThermoGenesis Holdings (THMOResearch Report) and SAGE Therapeutics (SAGEResearch Report) with bullish sentiments.

Zymeworks (ZYME)

In a report released yesterday, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Zymeworks. The company’s shares closed last Monday at $38.76, close to its 52-week high of $39.27.

According to TipRanks.com, Willey is a 5-star analyst with an average return of 24.3% and a 51.6% success rate. Willey covers the Healthcare sector, focusing on stocks such as Ra Pharmaceuticals, Seattle Genetics, and IGM Biosciences.

Currently, the analyst consensus on Zymeworks is a Strong Buy with an average price target of $43.60, an 11.3% upside from current levels. In a report issued on November 11, Wells Fargo also maintained a Buy rating on the stock with a $48.00 price target.

See today’s analyst top recommended stocks >>

ThermoGenesis Holdings (THMO)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on ThermoGenesis Holdings, with a price target of $7.50. The company’s shares closed last Monday at $3.62.

According to TipRanks.com, Ramakanth is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.9% and a 32.3% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals, IntelGenx Technologies, and Cellectar Biosciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ThermoGenesis Holdings with a $7.50 average price target.

SAGE Therapeutics (SAGE)

In a report released yesterday, Paul Matteis from Stifel Nicolaus reiterated a Buy rating on SAGE Therapeutics. The company’s shares closed last Monday at $151.52.

According to TipRanks.com, Matteis is a 5-star analyst with an average return of 20.1% and a 54.7% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, BioMarin Pharmaceutical, and ACADIA Pharmaceuticals.

SAGE Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $198.00, which is a 34.3% upside from current levels. In a report issued on November 12, Cowen & Co. also maintained a Buy rating on the stock with a $207.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.